|
US4722848A
(en)
|
1982-12-08 |
1988-02-02 |
Health Research, Incorporated |
Method for immunizing animals with synthetically modified vaccinia virus
|
|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
|
US5391481A
(en)
|
1990-08-31 |
1995-02-21 |
The Trustees Of Columbia University |
Antibody which is directed against and inhibits collagen binding to a VLA-1 epitope and uses thereof
|
|
GB9022040D0
(en)
|
1990-10-10 |
1990-11-21 |
Biopharm Ltd |
Platelet adhesion inhibitor
|
|
US5851794A
(en)
|
1990-10-22 |
1998-12-22 |
Alfa Laval Ab |
Collagen binding protein as well as its preparation
|
|
US5173414A
(en)
|
1990-10-30 |
1992-12-22 |
Applied Immune Sciences, Inc. |
Production of recombinant adeno-associated virus vectors
|
|
WO1993021226A1
(en)
|
1992-04-10 |
1993-10-28 |
The General Hospital Corporation |
Cartilage matrix protein and methods for use
|
|
US5491130A
(en)
|
1992-11-10 |
1996-02-13 |
The United States Of America As Represented By The Department Of Health And Human Services |
Peptide inhibitors of fibronectin and related collagen-binding proteins
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5849589A
(en)
|
1996-03-11 |
1998-12-15 |
Duke University |
Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
|
|
CA2255669A1
(en)
|
1996-05-16 |
1997-11-20 |
The Texas A & M University System |
Collagen binding protein compositions and methods of use
|
|
US7951917B1
(en)
|
1997-05-02 |
2011-05-31 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
ES2590912T3
(en)
|
1997-12-08 |
2016-11-24 |
Merck Patent Gmbh |
Heterodimeric fusion proteins useful for targeted immunotherapy and general immune system stimulation
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
US6387663B1
(en)
|
1998-07-31 |
2002-05-14 |
University Of Southern California |
Targeting pharmaceutical agents to injured tissues
|
|
AU1105700A
(en)
|
1998-10-09 |
2000-05-01 |
Med Immune, Inc. |
Decorin binding proteins dbp a and b and genes encoding them
|
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
EP1163253A2
(en)
|
1999-03-15 |
2001-12-19 |
The General Hospital Corporation |
Syndesmos and uses thereof
|
|
US6864235B1
(en)
|
1999-04-01 |
2005-03-08 |
Eva A. Turley |
Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
|
|
US6908994B1
(en)
|
1999-05-10 |
2005-06-21 |
The Texas A&M University System |
Collagen-binding proteins from enterococcal bacteria
|
|
AU5495500A
(en)
|
1999-06-16 |
2001-01-02 |
The Texas A & M University System |
Decorin binding protein essential peptides and methods of use
|
|
WO2000078800A2
(en)
|
1999-06-18 |
2000-12-28 |
Medimmune, Inc. |
Combined decorin binding protein and outer surface protein compositions and methods of use
|
|
CN1250288C
(en)
|
1999-12-15 |
2006-04-12 |
研究发展基金会 |
Beta glycan as an inhibin receptor and uses thereof
|
|
US6777547B1
(en)
|
2000-01-31 |
2004-08-17 |
Andreas Podbielski |
Collagen-binding proteins from streptococcus pyogenes
|
|
US6517838B1
(en)
|
2000-06-16 |
2003-02-11 |
The Texas A&M University System |
Decorin binding protein essential peptides and methods of use
|
|
AU2001292943A1
(en)
|
2000-09-21 |
2002-04-02 |
The Brigham And Women's Hospital, Inc. |
Prevention and treatment of streptococcal and staphylococcal infection
|
|
US20040236080A1
(en)
|
2001-06-22 |
2004-11-25 |
Hiroyuki Aburatani |
Cell proliferation inhibitors containing anti-glypican 3 antibody
|
|
US8192744B2
(en)
|
2002-08-26 |
2012-06-05 |
Ibcc Holding As |
Drug for treating states related to the inhibition of angiogenesis and/or endothelial cell proliferation
|
|
US7488792B2
(en)
|
2002-08-28 |
2009-02-10 |
Burnham Institute For Medical Research |
Collagen-binding molecules that selectively home to tumor vasculature and methods of using same
|
|
GB0406415D0
(en)
|
2004-03-22 |
2004-04-21 |
Inst Of Cancer Res The |
Materials and methods for treatment of cancer
|
|
US20070259380A1
(en)
|
2004-05-20 |
2007-11-08 |
Kyoichi Sumida |
Method for Measuring Hyaluronic Acid Using Hyaluronic Acid Binding Protein
|
|
EP1761782A2
(en)
|
2004-06-18 |
2007-03-14 |
Roche Diagnostics GmbH |
Use of protein cbp2 as a marker for colorectal cancer
|
|
CN102702353A
(en)
|
2004-07-09 |
2012-10-03 |
中外制药株式会社 |
Anti-glypican 3 antibody
|
|
WO2006023382A2
(en)
|
2004-08-23 |
2006-03-02 |
Albert Einstein College Of Medicine Of Yeshiva University |
Collagen vi and cancer
|
|
US20090142345A1
(en)
|
2005-03-15 |
2009-06-04 |
Takeda Pharmaceutical Company Limited |
Prophylactic/therapeutic agent for cancer
|
|
WO2006130974A1
(en)
|
2005-06-08 |
2006-12-14 |
Cangene Corporation |
Hyaluronic acid binding peptides enhance host defense against pathogenic bacteria
|
|
CN105330741B
(en)
|
2005-07-01 |
2023-01-31 |
E.R.施贵宝&圣斯有限责任公司 |
Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
|
|
PT1999154E
(en)
|
2006-03-24 |
2013-01-24 |
Merck Patent Gmbh |
Engineered heterodimeric protein domains
|
|
EP1864996A1
(en)
|
2006-06-06 |
2007-12-12 |
Helmholtz-Zentrum für Infektionsforschung GmbH |
Peptide associated with rheumatic fever (PARF) and its use as a diagnostic marker.
|
|
HU0600578D0
(en)
|
2006-07-13 |
2006-09-28 |
Szilak Labor Bioinformatikai E |
Nuclear protein transport
|
|
WO2008018519A1
(en)
|
2006-08-08 |
2008-02-14 |
Seikagaku Corporation |
Method for determination of molecular weight of hyaluronic acid
|
|
US8465732B2
(en)
|
2007-01-19 |
2013-06-18 |
Cornell Research Foundation, Inc. |
Endothelial cells expressing adenovirus E4ORF1 and methods of use thereof
|
|
AU2008275985B2
(en)
|
2007-07-17 |
2013-09-19 |
E. R. Squibb & Sons, L.L.C. |
Monoclonal antibodies against Glypican-3
|
|
AU2009204501B2
(en)
|
2008-01-07 |
2015-02-12 |
Amgen Inc. |
Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
|
|
JP5619603B2
(en)
|
2008-03-17 |
2014-11-05 |
国立大学法人宮崎大学 |
Method for detecting hepatoma cells using anti-glypican 3 antibody
|
|
US20090297479A1
(en)
|
2008-03-28 |
2009-12-03 |
Kiyoshi Ariizumi |
Dc-hil conjugates for treatment of t-cell disorders
|
|
CN107236044B
(en)
|
2008-04-02 |
2021-07-02 |
宏观基因有限公司 |
HER2/neu-specific antibodies and methods of use thereof
|
|
ES2399584T3
(en)
|
2008-04-15 |
2013-04-02 |
Wako Pure Chemical Industries, Ltd. |
New protein capable of binding to hyaluronic acid and procedure to measure hyaluronic acid using the same
|
|
EP2338055A4
(en)
|
2008-09-19 |
2012-10-31 |
Univ Pittsburgh |
MONOCLONAL CSPG4 ANTIBODIES FOR THE DIAGNOSIS AND TREATMENT OF BASAL-TYPE MAMMARY CARCINOMA
|
|
GB0818273D0
(en)
|
2008-10-06 |
2008-11-12 |
Cambridge Entpr Ltd |
Modulation of cellular activity and differentiation
|
|
KR101105428B1
(en)
|
2009-02-12 |
2012-01-17 |
경북대학교 산학협력단 |
Peptides Specific to Glycocan-3 Proteins
|
|
BRPI1012589A2
(en)
|
2009-04-07 |
2016-03-22 |
Roche Glycart Ag |
bispecific antibodies anti-erbb-3 / anti-c-met
|
|
WO2010129547A1
(en)
|
2009-05-04 |
2010-11-11 |
Purdue Research Foundation |
Collagen-binding synthetic peptidoglycans for wound healing
|
|
CN102573922B
(en)
|
2009-08-17 |
2015-08-05 |
罗切格利卡特公司 |
targeted immunoconjugate
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
LT2560993T
(en)
*
|
2010-04-20 |
2024-10-10 |
Genmab A/S |
Heterodimeric antibody fc-containing proteins and methods for production thereof
|
|
BR112012027001A2
(en)
|
2010-04-23 |
2016-07-19 |
Genentech Inc |
heteromultimeric protein production
|
|
JP5758004B2
(en)
|
2010-08-24 |
2015-08-05 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Bispecific antibodies comprising Fv fragments stabilized by disulfides
|
|
WO2012032080A1
(en)
|
2010-09-07 |
2012-03-15 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H |
Stabilised human fc
|
|
US8906649B2
(en)
|
2010-09-27 |
2014-12-09 |
Janssen Biotech, Inc. |
Antibodies binding human collagen II
|
|
MX352929B
(en)
|
2010-11-05 |
2017-12-13 |
Zymeworks Inc |
DESIGN OF STABLE HETERODIMERIC ANTIBODIES WITH MUTATIONS IN THE DOMAIN Fc.
|
|
US9260492B2
(en)
|
2010-11-15 |
2016-02-16 |
Pieris Ag |
Muteins of human lipocalin 2 with affinity for glypican-3 (GPC-3)
|
|
FI3434767T3
(en)
*
|
2010-11-30 |
2026-02-12 |
Chugai Seiyaku Kk |
Cytotoxicity-inducing therapeutic agent
|
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
|
MX340671B
(en)
*
|
2011-02-10 |
2016-07-20 |
Roche Glycart Ag |
Mutant interleukin-2 polypeptides.
|
|
TR201815420T4
(en)
|
2011-03-29 |
2018-11-21 |
Roche Glycart Ag |
Antibody fc variants.
|
|
ES2666550T3
(en)
|
2011-04-19 |
2018-05-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies specific for glypican 3 and their use
|
|
EA201892619A1
(en)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
IMMUNOCONJUGATES CONTAINING INTERLEUKIN-2 MUTANT POLYPETIPS
|
|
AU2012258706B2
(en)
|
2011-05-24 |
2017-05-18 |
Symic OA ApS |
Hyaluronic acid-binding synthetic peptidoglycans, preparation, and methods of use
|
|
WO2013012733A1
(en)
*
|
2011-07-15 |
2013-01-24 |
Biogen Idec Ma Inc. |
Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
|
|
US20150017121A1
(en)
*
|
2011-10-11 |
2015-01-15 |
Universitat Zurich |
Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy
|
|
WO2013070468A1
(en)
|
2011-11-08 |
2013-05-16 |
The Trustees Of The University Of Pennsylvania |
Glypican-3-specific antibody and uses thereof
|
|
EP2804586A4
(en)
|
2012-01-19 |
2016-03-16 |
Univ Johns Hopkins |
BIOMATERIALS COMPRISING HYALURONIC ACID-BINDING PEPTIDES AND BIFUNCTIONAL BIOPOLYMER MOLECULES FOR HYALURONIC ACID RETENTION AND TISSUE ENGINEERING APPLICATIONS
|
|
ES2740749T3
(en)
|
2012-04-20 |
2020-02-06 |
Merus Nv |
Methods and means for the production of Ig-like heterodimeric molecules
|
|
US9751919B2
(en)
|
2012-05-04 |
2017-09-05 |
Emergent Biosolutions Canada Inc. |
Antimicrobial compositions comprising a hyaluronic acid binding peptide and a β-lactam antibiotic
|
|
WO2013174783A1
(en)
|
2012-05-23 |
2013-11-28 |
Pieris Ag |
Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
|
|
WO2013181543A1
(en)
|
2012-06-01 |
2013-12-05 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
High-affinity monoclonal antibodies to glypican-3 and use thereof
|
|
MX2015000683A
(en)
|
2012-08-02 |
2015-04-10 |
Hoffmann La Roche |
Method for producing monomeric and multimeric molecules and uses thereof.
|
|
CN104508132B
(en)
|
2012-08-02 |
2017-09-15 |
弗·哈夫曼-拉罗切有限公司 |
Method for producing soluble FcR as an Fc fusion to an inert immunoglobulin Fc region and uses thereof
|
|
EP3434695B1
(en)
|
2012-08-07 |
2020-12-02 |
Roche Glycart AG |
Improved immunotherapy
|
|
JP6273205B2
(en)
*
|
2012-10-05 |
2018-01-31 |
協和発酵キリン株式会社 |
Heterodimeric protein composition
|
|
CN104955953B
(en)
|
2012-11-27 |
2019-04-26 |
亚洲大学校产学协力团 |
CH3 domain variant pair that efficiently induces heterodimer formation of antibody heavy chain constant region, preparation method and use thereof
|
|
US20140302037A1
(en)
*
|
2013-03-15 |
2014-10-09 |
Amgen Inc. |
BISPECIFIC-Fc MOLECULES
|
|
US10047167B2
(en)
|
2013-03-15 |
2018-08-14 |
Eli Lilly And Company |
Methods for producing fabs and bi-specific antibodies
|
|
WO2014145907A1
(en)
|
2013-03-15 |
2014-09-18 |
Xencor, Inc. |
Targeting t cells with heterodimeric proteins
|
|
CN105143252A
(en)
*
|
2013-03-15 |
2015-12-09 |
豪夫迈·罗氏有限公司 |
Il-22 polypeptides and il-22 Fc fusion proteins and methods of use
|
|
JP6618893B2
(en)
|
2013-04-29 |
2019-12-11 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Asymmetric antibodies with altered FC receptor binding and methods of use
|
|
WO2014194100A1
(en)
|
2013-05-29 |
2014-12-04 |
The Regents Of The University Of California |
Anti-cspg4 fusions with interferon for the treatment of malignancy
|
|
AR096891A1
(en)
|
2013-07-12 |
2016-02-03 |
Hanmi Pharm Ind Co Ltd |
CONJUGATE OF BIOMOLOGICALLY ACTIVE POLYPEPTIDE MONOMER AND CONJUGATE OF FRAGMENTO FC OF IMMUNOGLOBULINA, THAT SHOWS CLEARING THROUGH REDUCED RECEPTOR, AND THE METHOD FOR PREPARING THE SAME
|
|
UA117289C2
(en)
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
MULTISPECIFIC ANTIBODY
|
|
US20160032007A1
(en)
|
2014-04-28 |
2016-02-04 |
Duke University |
Human Antibody Fragments Against Chondroitin Sulfate Proteoglycan 4 (CSPG4)
|
|
KR20250165670A
(en)
|
2014-05-06 |
2025-11-26 |
제넨테크, 인크. |
Production of heteromultimeric proteins using mammalian cells
|
|
AU2015279316B2
(en)
|
2014-06-27 |
2021-03-04 |
Innate Pharma |
Multispecific NKp46 binding proteins
|
|
US10166304B2
(en)
|
2014-07-11 |
2019-01-01 |
Regents Of The University Of Minnesota |
Antibody fragments for detecting cancer and methods of use
|
|
MA40764A
(en)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
THERAPEUTIC AGENT INDUCING CYTOTOXICITY
|
|
PL3215528T3
(en)
|
2014-11-06 |
2020-01-31 |
F.Hoffmann-La Roche Ag |
Fc-region variants with modified fcrn-binding and methods of use
|
|
BR112017006591A2
(en)
|
2014-11-06 |
2018-01-16 |
Hoffmann La Roche |
heterodimeric polypeptide, pharmaceutical formulation and use of a heterodimeric polypeptide
|
|
CA2967350C
(en)
|
2014-11-12 |
2021-11-23 |
The General Hospital Corporation |
Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof
|
|
WO2016150884A1
(en)
|
2015-03-20 |
2016-09-29 |
Orbsen Therapeutics Limited |
Modulators of syndecan-2 and uses thereof
|
|
WO2016164408A1
(en)
|
2015-04-06 |
2016-10-13 |
The General Hospital Corporation |
Anti-cspg4 reagents and methods of treating cancer
|
|
CN113881694A
(en)
|
2015-06-24 |
2022-01-04 |
学校法人庆应义塾 |
Anti-glypican-1-immunizing antigen receptor
|
|
EP3331902B1
(en)
*
|
2015-08-07 |
2021-04-28 |
ALX Oncology Inc. |
Constructs having a sirp-alpha domain or variant thereof
|
|
EP3349770A1
(en)
|
2015-09-14 |
2018-07-25 |
Regents of the University of Minnesota |
Nk cells exhibiting an adaptive phenotype and methods for preparing and for using
|
|
US10584160B2
(en)
|
2015-09-23 |
2020-03-10 |
Bristol-Myers Squibb Company |
Glypican-3-binding fibronectin based scaffold molecules
|
|
US11098100B2
(en)
|
2015-10-06 |
2021-08-24 |
Regents Of The University Of Minnesota |
Therapeutic compounds and methods
|
|
KR101851380B1
(en)
|
2015-10-12 |
2018-04-23 |
아주대학교산학협력단 |
Method to generate CH3 domain mutant pairs of heterodimeric Fc using yeast mating and CH3 domain mutant pairs thereby
|
|
KR101796688B1
(en)
|
2015-10-29 |
2017-12-01 |
재단법인 목암생명과학연구소 |
Novel Antibody Against Glypican 3, and Pharmaceuitical Composition Comprising the Same
|
|
EP3478717B1
(en)
|
2016-07-04 |
2022-01-05 |
F. Hoffmann-La Roche AG |
Novel antibody format
|
|
AU2017305170A1
(en)
|
2016-08-02 |
2019-02-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof
|
|
WO2018030806A1
(en)
*
|
2016-08-10 |
2018-02-15 |
아주대학교산학협력단 |
Cytokine fused to immunoglobulin fc heterodimer and pharmaceutical composition comprising same
|
|
KR102050463B1
(en)
|
2016-08-10 |
2019-11-29 |
아주대학교산학협력단 |
Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same
|
|
KR101928981B1
(en)
*
|
2016-09-02 |
2018-12-13 |
고려대학교 산학협력단 |
Heterodimeric Fc-fused IL-21 and Pharmaceutical Composition Comprising the Same
|
|
CR20230179A
(en)
*
|
2016-10-14 |
2023-06-12 |
Xencor Inc |
IL15/IL15Ra HETERODIMERIC FC-FUSION PROTEINS
|
|
FI3582806T3
(en)
*
|
2017-02-20 |
2023-09-07 |
Dragonfly Therapeutics Inc |
HER2, NKG2D AND CD16 BINDING PROTEINS
|
|
US11248022B2
(en)
|
2017-03-08 |
2022-02-15 |
The Regents Of The University Of Michigan |
Glypican-3 peptide reagents and methods
|
|
BR112019020168A2
(en)
*
|
2017-03-27 |
2020-06-02 |
F. Hoffmann-La Roche Ag |
ANTIGEN BINDING RECEPTORS, TRANSDUCTED T CELLS, ISOLATED POLYNUCLEOTIDE, VECTOR, KITS, METHODS FOR TREATING A DISEASE AND INDUCING THE LYING OF A TARGET CELL AND USE OF THE ANTIGEN BINDING RECEPTOR
|
|
JP7254029B2
(en)
|
2017-04-26 |
2023-04-07 |
田辺三菱製薬株式会社 |
SYNDECAN-1 (CD138) binding agents and uses thereof
|
|
WO2018199318A1
(en)
|
2017-04-28 |
2018-11-01 |
国立大学法人高知大学 |
Anti-gpc-1 antibody
|
|
EP3630163A4
(en)
*
|
2017-05-24 |
2021-06-09 |
Pandion Operations, Inc. |
TARGETED IMMUNOTOLERANCE
|
|
JP2019014449A
(en)
|
2017-07-10 |
2019-01-31 |
トヨタ自動車株式会社 |
Vehicular power transmission device
|
|
WO2019051308A1
(en)
|
2017-09-07 |
2019-03-14 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and a tumor-associated antigen
|
|
BR112020005035A2
(en)
*
|
2017-09-21 |
2020-09-15 |
Merck Patent Gmbh |
fusion protein comprising fgf-18 portion
|
|
BR112020005676A2
(en)
*
|
2017-09-22 |
2020-10-20 |
WuXi Biologics Ireland Limited |
new bispecific polypeptide complexes
|
|
MX2020003497A
(en)
|
2017-10-20 |
2020-07-22 |
Hoffmann La Roche |
Method for generating multispecific antibodies from monospecific antibodies.
|
|
KR20200118824A
(en)
|
2018-02-08 |
2020-10-16 |
드래곤플라이 쎄라퓨틱스, 인크. |
Combination therapy for cancer involving multi-specific binding proteins that activate natural killer cells
|
|
DE102018208278A1
(en)
|
2018-05-25 |
2019-11-28 |
Robert Bosch Gmbh |
Operational assistance procedure, control unit, operational assistance system and working device
|
|
BR112021000392A2
(en)
*
|
2018-07-11 |
2021-04-06 |
Momenta Pharmaceuticals, Inc. |
COMPOSITIONS AND METHODS RELATED TO HANDLED FC-ANTIGEN CONNECTION CONSTRUCTIONS
|
|
SG11202103192RA
(en)
*
|
2018-10-03 |
2021-04-29 |
Xencor Inc |
Il-12 heterodimeric fc-fusion proteins
|
|
KR20210080460A
(en)
|
2018-10-23 |
2021-06-30 |
드래곤플라이 쎄라퓨틱스, 인크. |
Heterodimeric Fc-fused protein
|